Flavor of the week: antibiotics

Share this article:

AstraZeneca and Roche each entered collaborations to take on hospital infections.

As noted by PMLive, AstraZeneca's collaboration with the Agency for Science, Technology and Research to attack gram-negative infections appears somewhat at odds with the drugmaker's decision to scale back its infection R&D.

Roche announced Monday that it is pursuing antibiotic research with private drugmaker Polyphor, with which it will target pseudomonas aeruginosa, an infection which the companies say accounts for 10% of US hospital-acquired infections.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.